Exagen Diagnostics, a Vista, Calif.-based commercial-stage specialty diagnostic company, has raised $5.3m in equity funding.
The round was led by Tullis Health Investors, with participation from Sun Mountain Capital, Cottonwood Technology Fund, Mesa Verde Venture Partners and Epic Ventures.
The company intends to use the proceeds for market expansion and development of near-term pipeline products.
Led by Ron Rocca, president and CEO, and Curt LaBelle, M.D., chairman of Exagen and managing director at Tullis Health Investors, Exagen Diagnostics develops and commercializes novel diagnostic products that enable physicians to accurately diagnose patients. The company has CLIA-certified, CAP-accredited laboratory is Vista and corporate offices in Albuquerque, N.M.